Zanaflex (tizanidine) from Acorda Therapeutics is a short-acting drug used to manage spasticity associated with multiple sclerosis and spinal cord injury. It blocks nerve impulses (pain sensations) that are sent to the brain. Because of its temporary effect, treatment with tizanidine should be reserved for moments when spasticity relief is most important.

Its mechanism of action leads to spasticity reduction by blocking nerve impulses through pre-synaptic inhibition of motor neurons — without reducing muscle strength.

Tizanidine tablets or capsules should be taken by mouth with an initial dosage of 2 mg three times a day. For maintenance, a 2 to 4 mg increase may be prescribed at each dose until satisfactory reduction of muscle spasms is achieved — up to a maximum dose of 36 mg per day.

Most common side effects may include dry mouth, drowsiness, dizziness, asthenia, or infection.

Significant interactions can occur with tizanidine and other medicines, nutritional supplements, and certain herbal products. Patients should confer with their healthcare provider to ensure safe use.

Zanaflex is  available as a generic medicine. The generic is sold at lower prices than the brand name product.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

FDA Will Review Arbaclofen ER, Potential Oral Therapy for MS Spasticity

The U.S. Food and Drug Administration (FDA) has agreed to review  Osmotica Pharmaceuticals‘ amended request for the approval of arbaclofen extended release (ER) tablets to treat spasticity in people with multiple sclerosis (MS), the company announced. The regulatory agency found that the new drug application addressed all issues raised in a July 2016 action letter response to the […]

Trial of Cannabis Derivatives in Treating MS Spasticity to Open in Canada

The Multiple Sclerosis Society of Canada and its partner, the Canadian Institutes of Health Research (CIHR), have invested CA$1.5 million to open a clinical trial that will investigate the potential of two cannabis derivatives — cannabidiol (CBD) and tetrahydrocannabinol (THC) — in treating spasticity (muscle stiffness) and other symptoms of multiple sclerosis (MS). The money, worth about […]

Osmotica Amends NDA for Arbaclofen ER to Treat MS Spasticity

Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticity in people with multiple sclerosis (MS). Arbaclofen ER (brand name Ontinua), is an extended release formulation of arbaclofen, a compound similar to the muscle […]

Spasticity Scales May Not Reflect Sativex Benefits in MS Patients, Study Suggests

Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to reflect the therapy’s overall benefits beyond spasticity itself. […]

Nimodipine Can Prevent Spasticity Following Spinal Cord Injury, Mouse Study Shows

Nimodipine, an approved medication to prevent brain damage caused by hemorrhage, can be used to prevent spasticity following a spinal cord injury, a mouse study shows. In addition to spinal cord injury, nimodipine may be a promising treatment for neurodegenerative disorders such as multiple sclerosis (MS) and amyotrophic lateral sclerosis, in which spasticity often develops, investigators noted. […]

MS Patients Find Cannabis Helpful for Easing Pain, Spasticity, Study Reports

About 85% of people with multiple sclerosis (MS) using cannabis find it to be helpful for pain, and 79% find it eases spasticity, a new study reports. The study, “Cannabis use in people with multiple sclerosis and spasticity: A cross-sectional analysis,” was published in the journal Multiple Sclerosis and Related Disorders. A previous review study that examined the […]

THC:CBD Oral Spray Sativex Provides Consistent Relief for Treatment-resistant MS Spasticity

Sativex (nabiximols), a THC:CBD oral spray, consistently relieves the pain and severity of treatment-resistant spasticity in multiple sclerosis (MS) patients, according to a recent study. An analysis of the Sativex as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) study revealed that Sativex, used in conjunction with an anti-spasticity medication, provided strong and consistent relief from the symptoms and […]

I Am Beautifully Rare Despite SPMS

I have secondary progressive multiple sclerosis and I am rare. In honor of Rare Disease Day on Feb. 29, I honor myself. I honor you and anyone else with a rare disease. I have been asked if multiple sclerosis qualifies as a rare disease. It does if you have MS. I became rare on Nov. […]

Flowonix’s Prometra II Pump System Receives FDA Approval for Use with Intrathecal Baclofen

  The U.S. Food and Drug Administration (FDA) has granted approval to Flowonix Medical’s Prometra II Programmable Pump System for use with intrathecal baclofen for the treatment of spasticity across numerous conditions, including multiple sclerosis. Intrathecal baclofen — sold as Gablofen by Piramal, Lioresal by Saol Therapeutics, and also in generic formulations – is administered via an injection into […]